News
LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...
Fourth District Judge Amanda Brailsford in Boise on Thursday also granted provisional class-action status to a lawsuit ...
HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers ...
Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...
Adults with perinatally acquired HIV and those with HIV acquired via other routes had similar rates of AIDS-defining conditions during the transition to adult care.
When Robert Smith met his future girlfriend in 2010, he wanted to take things slowly. For Smith, no relationship had been ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
A federal judge extended a block on an Idaho law that uses an applicant’s immigration status to determine whether they’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results